Private Wealth Management
Family offices face an uncertain investment outlook following Russia’s invasion of Ukraine and the lingering impacts of the COVID-19 pandemic. The pandemic’s disruption to labor markets and global supply chains, combined with huge injections of liquidity through quantitative easing and low rates, has triggered a sharp rise in inflation worldwide.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of Rubrik, Inc. (RBRK $75.59), a leading vendor in the fast-evolving data protection (DP) industry, pioneering a next-generation approach to data backup and transforming perceptions of DP technology from “boring old backup” to a must-have cyber resilience platform.
William Blair initiated research coverage of Mersana Therapeutics, Inc. (MRSN $0.57), whose lead program emiltatug ledadotin is an ADC that targets B7-H4; it is in Phase I development for TNBC. The company is also developing a HER2-targeted immune-stimulating ADC, XMT-2056, in a Phase I solid tumor study.
Bullish predictions for the secondary market throughout 2024 proved accurate as volume hit record levels by yearend. Now, in 2025’s early weeks, market insiders remain optimistic—with expectations for continued LP- and GP-led growth.
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
